| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 19/12/2024 | 14:30 | GlobeNewswire Inc. | ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21 | NASDAQ:ABVC | ABVC BioPharma Inc |
| 11/12/2024 | 12:30 | GlobeNewswire Inc. | ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners | NASDAQ:ABVC | ABVC BioPharma Inc |
| 15/11/2024 | 21:31 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] | NASDAQ:ABVC | ABVC BioPharma Inc |
| 15/11/2024 | 01:33 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:ABVC | ABVC BioPharma Inc |
| 14/11/2024 | 15:25 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ABVC | ABVC BioPharma Inc |
| 14/11/2024 | 15:00 | GlobeNewswire Inc. | ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones | NASDAQ:ABVC | ABVC BioPharma Inc |
| 14/11/2024 | 14:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ABVC | ABVC BioPharma Inc |
| 22/10/2024 | 14:45 | GlobeNewswire Inc. | ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners | NASDAQ:ABVC | ABVC BioPharma Inc |
| 15/08/2024 | 13:30 | GlobeNewswire Inc. | ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements | NASDAQ:ABVC | ABVC BioPharma Inc |
| 07/08/2024 | 23:15 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:ABVC | ABVC BioPharma Inc |
| 02/08/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ABVC | ABVC BioPharma Inc |
| 26/07/2024 | 22:30 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:ABVC | ABVC BioPharma Inc |
| 17/05/2024 | 23:00 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:ABVC | ABVC BioPharma Inc |
| 15/05/2024 | 23:00 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB | NASDAQ:ABVC | ABVC BioPharma Inc |
| 18/04/2024 | 15:25 | GlobeNewswire Inc. | AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share | NASDAQ:ABVC | ABVC BioPharma Inc |
| 17/04/2024 | 15:00 | GlobeNewswire Inc. | ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M | NASDAQ:ABVC | ABVC BioPharma Inc |
| 10/04/2024 | 14:30 | GlobeNewswire Inc. | ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M | NASDAQ:ABVC | ABVC BioPharma Inc |
| 26/03/2024 | 13:30 | GlobeNewswire Inc. | ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M | NASDAQ:ABVC | ABVC BioPharma Inc |
| 21/03/2024 | 13:30 | GlobeNewswire Inc. | AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars | NASDAQ:ABVC | ABVC BioPharma Inc |
| 19/03/2024 | 13:30 | GlobeNewswire Inc. | ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine | NASDAQ:ABVC | ABVC BioPharma Inc |
| 14/03/2024 | 14:30 | GlobeNewswire Inc. | ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update | NASDAQ:ABVC | ABVC BioPharma Inc |
| 27/02/2024 | 14:30 | GlobeNewswire Inc. | ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars | NASDAQ:ABVC | ABVC BioPharma Inc |
| 16/02/2024 | 23:04 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] | NASDAQ:ABVC | ABVC BioPharma Inc |
| 15/02/2024 | 14:30 | GlobeNewswire Inc. | ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues | NASDAQ:ABVC | ABVC BioPharma Inc |
| 14/02/2024 | 01:59 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ABVC | ABVC BioPharma Inc |
| 12/02/2024 | 14:30 | GlobeNewswire Inc. | ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) | NASDAQ:ABVC | ABVC BioPharma Inc |
| 08/02/2024 | 15:17 | GlobeNewswire Inc. | ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share | NASDAQ:ABVC | ABVC BioPharma Inc |
| 12/01/2024 | 23:01 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:ABVC | ABVC BioPharma Inc |
| 03/01/2024 | 13:24 | GlobeNewswire Inc. | ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees | NASDAQ:ABVC | ABVC BioPharma Inc |
| 07/12/2023 | 14:30 | GlobeNewswire Inc. | ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study | NASDAQ:ABVC | ABVC BioPharma Inc |